Imidazole based kinesin spindle protein inhibitors

Abstract

This application claims substituted imidazole compounds as kinesin spindle protein (KSP) inhibitors. The claimed compounds are selective KSP inhibitors with activity against KSP ATPase as well as antiproliferative activity against a range of cancer cell lines. No specific advantage is given compared with other KSP inhibitors. This application represents part of a KSP program initiated at Chiron, which is now part of Novartis.

Keywords::

• anticancer
• antimitotics
• Eg5
• kinesin spindle protein

Acknowledgements

The author is employed by and has stock options in Kalypsys, Inc., which has had a KSP program.